Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 4—April 2025
Research

Carbapenem-Resistant, Virulence Plasmid–Harboring Klebsiella pneumoniae, United States

Jianping Jiang, Tengfei Long, Adeline R. Porter, Arianne Lovey, Annie Lee, Jesse Thomas Jacob, Cesar A. Arias, Robert Bonomo, Robert Kalayjian, Yanan Zhao, Frank R. DeLeo, David van Duin, Barry N. KreiswirthComments to Author , and Liang ChenComments to Author 
Author affiliation: Hackensack-Meridian Health Center for Discovery and Innovation, Nutley, New Jersey, USA (J. Jiang, T. Long, A. Lovey, A. Lee, Y. Zhao, B.N. Kreiswirth, L. Chen); National Institute of Allergy and Infectious Disease Rocky Mountain Laboratories, Hamilton, Montana, USA (A.R. Porter, F.R. DeLeo); Emory University, Atlanta, Georgia, USA (J.T. Jacob); Houston Methodist Hospital and Houston Methodist Research Institute, Houston, Texas, USA (C.A. Arias); Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA (R.A. Bonomo); Case Western Reserve University School of Medicine, Cleveland (R.A. Bonomo); MetroHealth Medical Center, Cleveland (R. Kalayjian); University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA (D. van Duin)

Main Article

Figure 4

Serum and PMN bactericidal activity in 6 clinical isolates in study of carbapenem-resistant, virulence plasmid–harboring Klebsiella pneumoniae isolates, United States. A–B) The indicated clinical isolates were cultured with 0%, 5%, 25%, or 83% NHS for 1 hour, and recovered viable bacteria were enumerated as both percentages (A) and absolute values (B). Asterisk (*) indicates p<0.05 vs. 0% serum by using a repeated-measures analysis of variance and Dunnett posttest; hash mark (#) indicates p<0.05 vs. ARLG-3254 in 25% or 83% NHS by using a t-test. C–D) Survival of clinical isolates determined following synchronized PMN phagocytosis assays at 30 or 60 min as described. Data are expressed as percentage survival (C) or colony-forming units (D). Results represent the mean (dots) + SD (error bars) of 3 separate experiments. Asterisk (*) indicates p<0.05 as determined by using a repeated-measures analysis of variance and Bonferroni posttest (selected pairs of data) or Kruskal-Wallis test and Dunn posttest for nonparametric analysis of ARLG-4744; hash mark (#) indicates p<0.05 vs. ARLG-3254 for 30 or 60 min in PMN by using a t-test. We conducted statistical analyses by using CFUs. NHS, normal human serum; PMN, polymorphonuclear neutrophils; ST, sequence type.

Figure 4. Serum and PMN bactericidal activity in 6 clinical isolates in study of carbapenem-resistant, virulence plasmid–harboring Klebsiella pneumoniae isolates, United States. A–B) The indicated clinical isolates were cultured with 0%, 5%, 25%, or 83% NHS for 1 hour, and recovered viable bacteria were enumerated as both percentages (A) and absolute values (B). Asterisk (*) indicates p<0.05 vs. 0% serum by using a repeated-measures analysis of variance and Dunnett posttest; hash mark (#) indicates p<0.05 vs. ARLG-3254 in 25% or 83% NHS by using a t-test. C–D) Survival of clinical isolates determined following synchronized PMN phagocytosis assays at 30 or 60 min as described. Data are expressed as percentage survival (C) or colony-forming units (D). Results represent the mean (dots) + SD (error bars) of 3 separate experiments. Asterisk (*) indicates p<0.05 as determined by using a repeated-measures analysis of variance and Bonferroni posttest (selected pairs of data) or Kruskal-Wallis test and Dunn posttest for nonparametric analysis of ARLG-4744; hash mark (#) indicates p<0.05 vs. ARLG-3254 for 30 or 60 min in PMN by using a t-test. We conducted statistical analyses by using CFUs. NHS, normal human serum; PMN, polymorphonuclear neutrophils; ST, sequence type.

Main Article

Page created: February 18, 2025
Page updated: March 11, 2025
Page reviewed: March 11, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external